Business Development Manager at BTO, Torsten Porwol, is in charge of handelling the business aspect of the CFS discovery published by the cancer researchers Olav Mella and Øysten Fluge at Haukeland Hospital in Bergen, Norway. The study targets CFS via B-cell depletion and indicates that CFS is an autoimmune disease, and considered a breakthrough in the treatment of this medical contidion. This discovery has resulted in media coverage worldwide, and on a business trip to the US two weeks ago with purpose to present the study to the pharmaceutical industry, mr. Porwol was interviewed by the White House Cronicle ME/CFS alert, which is published on YouTube
Also see interview in YouTube here (ME/CFS Alert, episode 12)
